Open Access<p>The Traditional Chinese Medicine Compound, GRS, Alleviates Blood–Brain Barrier Dysfunction</p>
Author(s) -
Yuanyuan Zhang,
Yang Hu,
Min Li,
Jieman Wang,
Gengshuo Guo,
Fang Li,
Boyang Yu,
Junping Kou
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s229302
Subject(s) - blood–brain barrier , pharmacology , medicine , matrix metalloproteinase , in vivo , downregulation and upregulation , tight junction , fasudil , cerebral blood flow , cofilin , phosphorylation , evans blue , mmp9 , chemistry , rho associated protein kinase , biology , actin cytoskeleton , biochemistry , cytoskeleton , central nervous system , cell , microbiology and biotechnology , gene
Traditional Chinese medicine (TCM) provides unique advantages for treatment of ischemic stroke, an aging-related vascular disease. Shengmai powder (GRS) is composed of three active components, specifically, ginsenoside Rb1, ruscogenin and schisandrin A, at a ratio of 6:0.75:6. The main objective of this study was to evaluate the effects of GRS on blood-brain barrier (BBB) dysfunction under conditions of middle cerebral artery occlusion/reperfusion (MCAO/R).